Goldline Pharmaceutical IPO: 840x bids, May 19 listing

Goldline Pharmaceutical IPO closes: key dates investors tracked

Goldline Pharmaceutical’s SME IPO has closed for subscription, according to posts circulating on Reddit and market forums. The issue was open between May 12 and May 14, 2026, as widely shared in IPO trackers. The BSE SME listing date repeatedly mentioned is May 19, 2026. The basis of allotment was expected to be finalised by May 15, 2026, per multiple posts. Several reminders also flagged the UPI mandate cut-off as 5:00 PM on May 14, 2026. Conversations focused less on the business story and more on the unusual demand numbers. Many users treated it as a “subscription event” rather than a valuation debate. The core question across threads was simple - how can a small issue see such large multiples.

Price band, face value, and how big one application gets

The price band was shared as ₹41 to ₹43 per share, with a face value of ₹10. Lot size was 3,000 shares, which is typical for many SME IPOs but still large in rupee terms here. Retail investors were required to apply for a minimum of two lots. That makes the minimum retail application 6,000 shares. At the upper band, the minimum retail outlay was repeatedly quoted as ₹2,58,000. Posts also stated the HNI (NII) entry point starts at three lots, or 9,000 shares. That translates to ₹3,87,000 at ₹43, as shared in the lot-size table. For bNII, the minimum was cited as eight lots, or 24,000 shares, requiring ₹10,32,000.

Subscription numbers went viral, but snapshots differed

Social posts carried multiple “latest” subscription snapshots from different times on May 14. One widely shared end-of-bidding headline number was 781.85x total subscription. Another tracker snapshot circulating for May 14 showed 840.74x overall subscription. Earlier intraday numbers also did the rounds, including 437.11x at around 1:06 PM. These differences matter because many readers saw only one screenshot and treated it as the final figure. The category mix, however, was directionally similar across posts - NII demand dominated, followed by retail, and then QIB. Below is a consolidated view of the key snapshots shared online. All figures are as posted on social media trackers and can vary by timestamp.

Who drove demand: NIIs and retail in the spotlight

The strongest demand discussed online came from the non-institutional bucket. In one widely shared table, NII subscription was 1,227.90x, while another snapshot put NII at 1,662.04x. Users also broke NII into sNII and bNII for more colour. bNII (bids above ₹10 lakh) was quoted at 1,995.14x in the “latest snapshot” post. sNII (bids below ₹10 lakh) was quoted at 995.84x in the same snapshot. Retail subscription was consistently high in the posts, commonly shown at 881.15x by close. QIB participation was also strong in the shared final-day table, with QIB at 180.22x. The overall narrative on forums was that this looked like an HNI-led book, with retail also chasing the momentum.

Day-wise trend: from day-one full book to day-three surge

Several posters highlighted that the IPO was “booked within minutes” on day one. The day-wise tables shared showed day-one overall subscription around 22.35x. On day two, screenshots typically showed a sharp jump, with total around 93.19x in one tracker. By day three, the same tracker series displayed a steep surge to 781.85x overall. Another set of day-wise numbers circulating showed different intermediate totals, including 100.14x on day two and 211.41x on day three for a separate snapshot series. The differences appear to come from different reporting cut-offs rather than category definitions. Still, the common thread was acceleration late in the book. Commenters linked this kind of surge to last-day HNI bidding patterns typical in SME issues.

Anchor book details that social media highlighted

The anchor allocation details were shared with named funds and allotment counts. Two anchor investors were listed in posts: UPSURGE OPPORTUNITIES FUND I and VIKASA INDIA EIF I FUND-SHARE CLASS P. Each was shown as allotted 3,66,000 shares, taking the anchor total to 7,32,000 shares. The amount raised via the anchor book was stated as ₹3.15 crore in the table. The same table showed the anchor portion as 27.11% of the issue. Lock-in terms were also circulated in a timeline format. The posts stated 50% of anchor shares are locked for 30 days, ending June 10, 2026. The remaining shares were stated to be locked for 90 days, ending August 9, 2026.

Issue size, share count, and reservation structure

Posts described the IPO as an SME book-building issue of 27,00,000 equity shares. The capital raise figure shared was around ₹12 crore, with some posts also quoting about ₹11.61 crore. A separate line item stated 1,38,000 shares were reserved for the market maker. Reservation rules were summarised as QIB not more than 49.65% of the net issue. NII (HNI) was shown as not less than 15.22% of the net issue. Retail was shown as not less than 35.13% of the net issue. Some tracker pages also presented a share-offered split including QIB 5,40,000 shares, NII 3,90,000 shares, and retail 9,00,000 shares, alongside the anchor portion. These numbers were shared as “IPO reservation” breakdowns rather than final allotment outcomes. Investors on forums mainly used these splits to estimate allocation odds under heavy oversubscription.

GMP chatter was mixed, adding to the debate

Grey market premium (GMP) became a frequent argument point in the threads. One post stated GMP was ₹0 at present, calling it a sign of mixed interest and a possible debut near the ₹43 offer price. In contrast, Hindi-language market posts claimed a GMP of ₹18, framing it as about 41.8% above the cap price. The coexistence of ₹0 and ₹18 GMP claims in the same social stream led to confusion. Some users treated the GMP as unreliable for SME IPOs due to thin informal markets. Others treated GMP as a sentiment gauge that can change rapidly into listing week. The only consistent takeaway across posts was that GMP signals were not unanimous. That uncertainty kept the focus on subscription data rather than listing-day projections.

Risk notes shared online and practical takeaways

Beyond the demand numbers, a few posts outlined risk factors in plain terms. One write-up described the offering as “moderate to high-risk” and urged careful evaluation. It cited complete dependence on third-party manufacturers as a key business risk. It also mentioned promoter group conflicts as a concern flagged by commentators. The same post described the issue as “conservatively priced” at 4.1x to 4.3x P/E, though forum users did not add additional financial details. Practical guidance in the threads focused on the application process through ASBA or UPI via brokers. Many reminders emphasised that funds remain blocked until allotment under ASBA and UPI mandates. With allotment expected by May 15 and listing on May 19, most discussions shifted to allotment probability and post-listing liquidity typical of BSE SME shares.